Nature Communications (Apr 2018)
LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus
- Nadia Cobo-Vuilleumier,
- Petra I. Lorenzo,
- Noelia García Rodríguez,
- Irene de Gracia Herrera Gómez,
- Esther Fuente-Martin,
- Livia López-Noriega,
- José Manuel Mellado-Gil,
- Silvana-Yanina Romero-Zerbo,
- Mathurin Baquié,
- Christian Claude Lachaud,
- Katja Stifter,
- German Perdomo,
- Marco Bugliani,
- Vincenzo De Tata,
- Domenico Bosco,
- Geraldine Parnaud,
- David Pozo,
- Abdelkrim Hmadcha,
- Javier P. Florido,
- Miguel G. Toscano,
- Peter de Haan,
- Kristina Schoonjans,
- Luis Sánchez Palazón,
- Piero Marchetti,
- Reinhold Schirmbeck,
- Alejandro Martín-Montalvo,
- Paolo Meda,
- Bernat Soria,
- Francisco-Javier Bermúdez-Silva,
- Luc St-Onge,
- Benoit R. Gauthier
Affiliations
- Nadia Cobo-Vuilleumier
- Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC
- Petra I. Lorenzo
- Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC
- Noelia García Rodríguez
- Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC
- Irene de Gracia Herrera Gómez
- Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC
- Esther Fuente-Martin
- Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC
- Livia López-Noriega
- Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC
- José Manuel Mellado-Gil
- Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC
- Silvana-Yanina Romero-Zerbo
- Unidad de Gestión Clínica Intercentros de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga, Universidad de Málaga
- Mathurin Baquié
- Neurix SA
- Christian Claude Lachaud
- Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC
- Katja Stifter
- Ulm University Hospital
- German Perdomo
- Facultad de Ciencias de la Salud, Universidad de Burgos
- Marco Bugliani
- Department Clinical and Experimental Medicine, University of Pisa—AOUP University Hospital
- Vincenzo De Tata
- Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa
- Domenico Bosco
- Cell Isolation and Transplantation Centre, University Hospital
- Geraldine Parnaud
- Cell Isolation and Transplantation Centre, University Hospital
- David Pozo
- Department of Cell Dynamics and Signalling, CABIMER-Andalusian Center for Molecular Biology and Regenerative Medicine
- Abdelkrim Hmadcha
- Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC
- Javier P. Florido
- Clinical Bioinformatics Area, Fundación Progreso y Salud, Consejería de Salud
- Miguel G. Toscano
- Amarna Therapeutics
- Peter de Haan
- Amarna Therapeutics
- Kristina Schoonjans
- Laboratory of Metabolic Signaling, EPFL
- Luis Sánchez Palazón
- Biological Resources, CABIMER-Andalusian Center for Molecular Biology and Regenerative Medicine
- Piero Marchetti
- Department Clinical and Experimental Medicine, University of Pisa—AOUP University Hospital
- Reinhold Schirmbeck
- Ulm University Hospital
- Alejandro Martín-Montalvo
- Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC
- Paolo Meda
- Department of Cell Physiology and Metabolism, University of Geneva
- Bernat Soria
- Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC
- Francisco-Javier Bermúdez-Silva
- Unidad de Gestión Clínica Intercentros de Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga, Universidad de Málaga
- Luc St-Onge
- Benoit R. Gauthier
- Department of Cell Regeneration and Advanced Therapies, Andalusian Center for Molecular Biology and Regenerative Medicine-CABIMER, Junta de Andalucia-University of Pablo de Olavide-University of Seville-CSIC
- DOI
- https://doi.org/10.1038/s41467-018-03943-0
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 15
Abstract
Type 1 diabetes mellitus (T1DM) is characterized by beta cell loss because of an autoimmune attack. Here the authors show that an agonist for LRH-1/NR5A2, a nuclear receptor known to be protective against beta cell apoptosis, inhibits immune-mediated inflammation and hyperglycemia in T1DM mouse models.
